Neutropenıa Secondary to Sars-Cov2 Vaccınatıon in Post-Hematopoıetıc Stem Cell Transplant (Hsct) Patıents

Main Article Content

LUIS MIGUEL JUAREZ-SALCEDO
La Princesa University Hospital

Samantha Feijóo
Malignant Hematology Department. La Princesa University Hospital. Madrid, Spain.

Cristina García
Alejandro Alonso
Beatriz Aguado
Javier Ortiz
Angela Figuera
Rafael de la Cámara

Keywords

bone marrow transplantation, Neutropenia, anti SARS-CoV-2 vaccine

Abstract

SARS-Cov2 s, caused a high mortality in patients with some degree of immunosuppression, like those that receive a hematopoietic progenitor transplant. Since December 2020, several vaccines have been developed having been key in decreasing complications and mortality in this group of patients. Different articles have described the presence of thrombopenia related to the administration of vaccines, however, there are few data on the occurrence of neutropenia as a side effect after administration. We present several cases of neutropenia (defined as absolute neutrophil count (ANC) less than 2,000/mm3), after vaccination in hematopoietic progenitor transplant (HPT) recipients performed in our center during 2021.


 

Downloads

Download data is not yet available.


Abstract 571
PDF Downloads 664
HTML Downloads 261

References

1. Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2021;17(3):519–527.
2. Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021;384(11):10.
3. Baden LR, El Sahly HM, Essink B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
4. Lee EJ, Cines DB, Gernsheimer T. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534–537.
5. Perricone C, Ceccarelli F, Nesher G. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol Res. 2014;60(2-3):226–235.
6. Ali H, Ngo D, Aribi A, Arslan S, Dadwal S, Marcucci G, Nakamura R, Forman SJ, Chen J, Al Malki MM. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplant Cell Ther. 2021 Nov;27(11):938.e1-938.e6.
7. Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, Beyar-Katz O, et al. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study. Transplant Cell Ther. 2021 Sep;27(9):788-794.

Article Sidebar

PDF HTML
Published
Feb 28, 2023
DOI https://doi.org/10.4084/MJHID.2023.014

Article Details

How to Cite

JUAREZ-SALCEDO, L. M. (2023) “Neutropenıa Secondary to Sars-Cov2 Vaccınatıon in Post-Hematopoıetıc Stem Cell Transplant (Hsct) Patıents”, Mediterranean Journal of Hematology and Infectious Diseases, 15(1), p. e2023014. doi: 10.4084/MJHID.2023.014.
Issue
Vol. 15 No. 1 (2023): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Letters to the Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.